IceCure Medical's ProSense® Cryoablation Proves Highly Effective for Breast Fibroadenomas in New Study

summarizeSummary

IceCure Medical announced the publication of an independent study in PLOS One, demonstrating its ProSense® cryoablation system is safe and highly effective for treating breast fibroadenomas, achieving 92.9% volume reduction.

check_boxKey Events

• Independent Study Published

  An independent, investigator-initiated study evaluating ProSense® for breast fibroadenomas was published in the peer-reviewed journal PLOS One.

• Strong Efficacy Demonstrated

  The study found ProSense® cryoablation resulted in a 92.9% median volume reduction of fibroadenomas one-year post-treatment.

• Potential Impact on Treatment Guidelines

  IceCure believes these findings may contribute to updates in treatment guidelines for non-cancerous breast tumors by medical societies, including the American Society of Breast Surgeons.

• Addresses Large Market

  The company estimates cryoablation could address approximately 63,000 cases of fibroadenoma excision in the U.S. annually, with ProSense® already having FDA clearance for this indication.

auto_awesomeAnalysis

This filing reports the publication of a significant independent study in a peer-reviewed journal, PLOS One, which validates the safety and effectiveness of IceCure's ProSense® cryoablation system for treating breast fibroadenomas. The demonstrated 92.9% volume reduction at one year is a strong clinical outcome for a common benign breast lesion. This data, especially for larger lesions and using multiple cryoprobe relocations, could lead to updates in treatment guidelines by medical societies, potentially expanding the market for ProSense® as an alternative to surgical excision. Given the company's recent positive news flow, including strong preliminary sales and successful clinical trial follow-ups, this publication further strengthens the commercial prospects and clinical adoption of its core product.